Cargando…
Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
Chimeric antigen receptor T cell immunotherapy is a promising therapeutic strategy for treating tumors, demonstrating its efficiency in eliminating several hematological malignancies in recent years. However, a major obstacle associated with current chimeric antigen receptor T cell immunotherapy is...
Autores principales: | Bai, Yun, Kan, Shifeng, Zhou, Shixin, Wang, Yuting, Xu, Jun, Cooke, John P, Wen, Jinhua, Deng, Hongkui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860832/ https://www.ncbi.nlm.nih.gov/pubmed/27462436 http://dx.doi.org/10.1038/celldisc.2015.40 |
Ejemplares similares
-
Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA
por: Bai, Yun, et al.
Publicado: (2016) -
Chimeric Antigen Receptor–modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model
por: Teng, Ruidi, et al.
Publicado: (2019) -
Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
por: Otáhal, Pavel, et al.
Publicado: (2015) -
Programmed death‐ligand 1 expression on CD22‐specific chimeric antigen receptor‐modified T cells weakens antitumor potential
por: Liu, Jie, et al.
Publicado: (2022) -
Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo
por: Sommermeyer, Daniel, et al.
Publicado: (2015)